OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

TILT-123

aka Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)

TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.